Medical Condition News

RSS

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

The world's first inclined beam treatment room is open and treating patients at the ProCure Proton Therapy Center in Oklahoma City. The third of four treatment rooms at the Oklahoma Center is treating a wide range of tumors with proton therapy, an important alternative to X-ray radiation in treating cancer.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Research team to receive AACR Team Science Award

The fourth annual American Association for Cancer Research Team Science Award will be given to Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team at the AACR 101st Annual Meeting 2010. This research team is comprised of interdisciplinary investigators from the Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and Harvard Medical School.

15 Apr 2010

New findings may aid in developing medications for atherosclerosis and insulin resistance

Scientists from Eastern Virginia Medical School (EVMS) recently presented preliminary research findings that identify a specific gene as a potential new target for treating obesity-related diseases.

15 Apr 2010

Albert Einstein College of Medicine receives grant to study link between housing status and cardiovascular health

Albert Einstein College of Medicine of Yeshiva University has been awarded $750,000 by the John D. and Catherine T. MacArthur Foundation to study the impact of housing on the cardiovascular health of Latinos in the Bronx.

15 Apr 2010

New UCLA study compares safety and efficacy of angioplasty to bypass surgery

At 56, Tim Obrenski found himself getting so exhausted that he couldn't even pull weeds from his garden. A visit to the cardiologist uncovered a major blockage in his heart's left main artery, and he was told he needed bypass surgery.

15 Apr 2010

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

15 Apr 2010

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

BIOTRONIK SE & Co. KG today announced the European launch after receiving CE Mark approval for its new Reocor external pacemakers, available in two models for dual and single chamber pacing therapy.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Avid Radiopharmaceuticals, Inc. today announced the presentation of interim data from its landmark florbetapir "Image-to-Autopsy" Phase III study. These data come from the first cohort of subjects in the trial and are the first ever Phase III results for an agent designed to image Alzheimer's disease pathology.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

UCSF: Obesity prevention strategies must start as early as possible

To be a truly comprehensive and successful anti-obesity program, First Lady Michelle Obama's "Let's Move" campaign must include interventions that target pregnant women, infants, and pre-school-age children, UCSF experts say.

15 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Scientists at Birmingham Children's Hospital and the Universities of Nottingham and Southampton have developed new guidelines that should help doctors to diagnose brain tumours in children more quickly.

15 Apr 2010

Researchers identify gene that appears to increase risk of Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's disease. The research will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that it has completed patient enrollment in a Phase 1 clinical trial evaluating the intravenous (IV) administration of JX-594, the company's lead product for the treatment of solid tumors. Jennerex expects to report the results from this trial at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in May 2010.

15 Apr 2010

New research indicates exercise-based rehabilitation can benefit heart failure patients

Your heart is an incredible muscle, pumping an estimated 2,000 gallons of blood through about 60,000 million miles of blood vessels — and beating maybe 100,000 times a day, year after year after year.

15 Apr 2010

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

Molecular biologist Jonathan Brody, Ph.D., assistant professor, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, has been awarded a 2010 Pancreatic Cancer Action Network - American Association of Cancer Research Career Development Award in memory of Skip Viragh.

15 Apr 2010

UnitedHealth partners with Walgreens and YMCA to control diabetes

The New York Times: "The UnitedHealth Group, one of the nation's largest health insurers, is teaming up with the Y.M.C.A. and retail pharmacies to try a new approach to one of the nation's most serious and expensive medical problems: Type 2 Diabetes. Rather than simply continuing to pay ever-higher medical claims to care for its diabetic customers, UnitedHealth is paying the Y.M.C.A. and pharmacists to keep people healthier."

15 Apr 2010

PROP compound linked to obesity and risk of cardiovascular disease

Whether or not you can taste a bitter compound called 6-n-propylthiouracil (or PROP) may help Professor Beverly Tepper identify your risk for becoming obese and/or developing cardiovascular disease.

15 Apr 2010

Medical Condition News

ProCure Proton Therapy Center treats cancer patients with proton therapy technology

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Research team to receive AACR Team Science Award

New findings may aid in developing medications for atherosclerosis and insulin resistance

Albert Einstein College of Medicine receives grant to study link between housing status and cardiovascular health

New UCLA study compares safety and efficacy of angioplasty to bypass surgery

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

BIOTRONIK launches new Reocor external pacemakers following European CE Mark approval

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

UCSF: Obesity prevention strategies must start as early as possible

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

Scientists develop new guidelines to help doctors diagnose brain tumours in children

Researchers identify gene that appears to increase risk of Alzheimer's disease

Enrollment complete in Jennerex' Phase 1 trial of JX-594 IV administration for solid tumors

New research indicates exercise-based rehabilitation can benefit heart failure patients

Molecular biologist awarded 2010 Pancreatic Cancer Action Network - AACR Career Development Award

UnitedHealth partners with Walgreens and YMCA to control diabetes

PROP compound linked to obesity and risk of cardiovascular disease

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News